What's in Upsher-Smith Laboratories's pipeline?

Upsher-Smith Laboratories has 3 drugs in our index: 2 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Upsher-Smith Laboratories's portfolio?

Top competitors by shared drug class: Aurobac Therapeutics SAS, Eisai Korea Inc., Impax Laboratories, LLC, Janssen Korea, Ltd., Korea, Johnson & Johnson Taiwan Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/upsher-smith-laboratories.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Upsher-Smith Laboratories — Portfolio Competitive Intelligence Brief

Upsher-Smith Laboratories pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Qudexy XR	Qudexy XR	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor; voltage-gated sodium channels	Neurology
Vogelxo	Vogelxo	marketed			Other
USL255	USL255	phase 3	sodium-activated potassium channel inhibitor	Nav1.5	Cardiovascular

Therapeutic area mix

Cardiovascular · 1
Neurology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Aurobac Therapeutics SAS · 1 shared drug class
Eisai Korea Inc. · 1 shared drug class
Impax Laboratories, LLC · 1 shared drug class
Janssen Korea, Ltd., Korea · 1 shared drug class
Johnson & Johnson Taiwan Ltd · 1 shared drug class
Kasr El Aini Hospital · 1 shared drug class
Maimonides Medical Center · 1 shared drug class
Mario Negri Institute for Pharmacological Research · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Upsher-Smith Laboratories:

Cite this brief

Drug Landscape (2026). Upsher-Smith Laboratories — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/upsher-smith-laboratories. Accessed 2026-05-14.